Introductory Paragraph {#S1}
======================

Pancreatic cancer is the fourth leading cause of cancer death in the developed world^[@R1]^. Both inherited high-penetrant mutations in *BRCA2*^[@R2]^, *ATM*^[@R3]^, *PALB2*^[@R4]^, *BRCA1*^[@R5]^, *STK11*^[@R6]^, *CDKN2A*^[@R7]^ and mismatch repair genes^[@R8]^ as well as low-penetrant loci are associated with increased risk^[@R9]--[@R12]^. To identify novel loci, we performed a genome-wide association study on 9,925 pancreatic cancer cases and 11,569 controls, including 4,164 newly genotyped cases and 3,792 controls in 9 studies from North America, Central Europe and Australia. Three newly associated regions were identified: 17q25.1 (*LINC00673*, rs11655237, OR=1.26, 95%CI:1.19--1.34, P=1.42×10^−14^), 7p13 (*SUGCT*, rs17688601, OR=0.88, 95%CI:0.84--0.92, *P*=1.41×10^−8^), and 3q29 (*TP63*, rs9854771, OR=0.89, 95%CI:0.85--0.93, P=2.35×10^−8^). Significant association was detected on 2p13.3 (*ETAA1*, rs1486134, OR=1.14, 95%CI:1.09--1.19, *P*=3.36×10^−9^), a region with prior suggestive evidence in the Han Chinese^[@R12]^. We replicate previously reported associations at 9q34.2(*ABO*)^[@R9]^, 13q22.1(*KLF5*)^[@R10]^, 5p15.33 (*TERT, CLPTM1*)^[@R10],[@R11]^, 13q12.2 (*PDX1*)^[@R11]^, 1q32.1(*NR5A2*)^[@R10]^, 7q32.3(*LINC-PINT*)^[@R11]^, 16q23.1(*BCAR1*)^[@R11]^ and 22q12.1 (*ZNRF3*)^[@R11]^. Our study identifies novel loci associated with pancreatic cancer risk.

Main Text {#S2}
=========

We conducted a two-stage genome-wide association study (GWAS) of pancreatic cancer ([Fig. 1](#F1){ref-type="fig"}). First, genome-wide genotyping of 8052 subjects from nine studies within the Pancreatic Cancer Case-Control Consortium (PanC4) ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) was conducted using the HumanOmniExpressExome-8v1 array. The overall study was approved by the Johns Hopkins Institutional Review Board (IRB). Each individual study obtained IRB approval from their parent institution. After quality control (Online Methods, [Fig. 1](#F1){ref-type="fig"}, [Supplementary Table 2](#SD1){ref-type="supplementary-material"}), 7,956 individuals (4,164 cases and 3,792 controls) and 654,470 SNPs with call rates greater than 98% were analyzed. Unconditional logistic regression analysis adjusted for age and the first seven principal component eigenvectors was conducted under the log-additive genetic model ([Fig. 2](#F2){ref-type="fig"}, [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}).

Analysis of 7,956 newly genotyped PanC4 individuals identified a novel locus at 17q25.1 (*LINC00673,* rs7214041, OR=1.38, 95%CI:1.26--1.51, *P*=1.95×10^−10^) significantly associated with pancreatic cancer risk ([Table 1](#T1){ref-type="table"}, column 'PanC4'). In addition we replicate regions that had previously been reported to be associated with pancreatic cancer in the Caucasian population ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). These include: 9q34.2^[@R9]^ (*ABO,* rs505922, OR=1.27, 95%CI:1.19--1.35, *P*=1.72×10^−13^), 13q22.1^[@R10]^ (*KLF5*, rs9543325, OR=1.24, 95%CI:1.16--1.32, *P*=2.26×10^−10^), 5p15.33^[@R10]^ (*CLPTM1*, rs401681, OR=1.2, 95% CI:1.13--1.28, *P*=2.7×10^−8^), 13q12.2^[@R11]^ (*PDX1*, rs9581943, OR=1.17, 95%CI:1.10--1.24, *P*=1.94×10^−7^), 1q32.1^[@R10]^ (*NR5A2*, rs3790844, OR=0.83, 95%CI:0.77--0.90, *P*=3.05×10^−6^), 7q32.3^[@R11]^ (*LINC-PINT*, rs6971499, OR=0.81, 95%CI:0.74--0.88, P=7.1×10^−6^), 5p15.33^[@R11]^ (*TERT*, rs2736098, OR=0.85, 95%CI: 0.78--0.93, P=2.31×10^−5^), 16q23.1^[@R11]^ (*BCAR1*, rs7190458, OR=1.4, 95%CI=1.22--1.60, P=1.01×10^−4^), and 22q12.1^[@R11]^ (*ZNRF3*, rs16986825, OR=1.14, 95% CI= 1.04--1.24, P= 2.72×10^−3^). In contrast, other than 2p13.3 (*ETAA1*, rs2035565, OR=1.15, 95%CI=1.07--1.25, P=2.69×10^−4^) ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}) we observed no evidence of association (P\>0.05) for SNPs previously reported to be associated (P\<1×10^−6^) with pancreatic cancer in Asian populations^[@R12],[@R13]^. While all ethnic groups were included in our analyses, over 92% of our study population reported Caucasian ancestry. We obtained similar results when analysis was limited to individuals reporting European ancestry. Because of limited sample sizes we did not conduct independent analysis of other ethnic groups(results not shown).

We then conducted a genome-wide meta-analysis of the PanC4 data with data from PanScan 1^[@R9]^ and PanScan 2^[@R10]^ (Combined Stage 1, [Fig. 1](#F1){ref-type="fig"}). After quality control (Online Methods and [Supplementary Table 4](#SD1){ref-type="supplementary-material"}), we analyzed 528,179 SNPs and 3,746 individuals (1,856 cases and 1,890 controls) from PanScan 1 and 557,555 SNPs and 3,300 individuals (1,618 cases and 1,682 controls) from PanScan 2. Since the genotyping platforms differed across studies, missing genotypes were imputed using IMPUTE v2^[@R14]^, with 1000 Genomes^[@R15]^ (release Dec 2013) and HapMap3^[@R16]^ (release \#2,2009) as reference panels. For PanScan 1 and PanScan 2, we conducted association analysis using unconditional logistic regression including age and the first four principal components eigenvectors as covariates. Data from PanC4, PanScan 1, and PanScan 2 were combined (7,638 cases and 7,364 controls and 866,891 SNPs) and analyzed using a fixed-effects model implemented in METAL^[@R17]^ ([Fig. 3](#F3){ref-type="fig"}). A QQ plot ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}) indicated appropriate control of type-1 errors, with λ values of 1.025 for PanC4, 0.998 for PanScan 1, and 1.017 for PanScan 2.

The Combined Stage 1 Analysis ([Table 1](#T1){ref-type="table"}, column 'Combined Stage 1') yielded a second novel region of association at 3q29 (*TP63*, rs9854771, OR=0.87, 95%CI:0.83--0.92, P=4.08×10^−8^). A second SNP on 17q25.1 (rs11655237, OR=1.27, 95%CI:1.19--1.36, P=6.74×10^−12^), which is in high LD (r^2^=0.95) with rs7214041, also gave significant evidence of association in these combined data.

We next conducted a Stage 2 analysis in an independent set of 2,497 cases and 4,611 controls from the PANDoRA consortium^[@R18]^. We selected twenty-five SNPs from 23 independent regions ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}) with p-values below 10^−5^ in either PanC4 or the Combined Stage 1 analyses. When multiple SNPs per region were associated, the most significant SNP was selected; SNPs on 17q25.1 and 2p13.3 were exceptions. After quality control (Online Methods, [Supplementary Table 6](#SD1){ref-type="supplementary-material"}), 2,287 cases and 4,205 controls from the PANDoRA study were analyzed. Age-adjusted association analyses by country were carried out, and results were combined using a fixed-effect model. We observed independent evidence of association at 17q25.1 in the PANDoRA study ([Table 1](#T1){ref-type="table"}, column 'PANDoRA': rs7214041, OR=1.25, 95%CI:1.11--1.41, *P*=3.37×10^−4^).

Combined analysis of the Stage 1 and 2 data for the 25 SNPs ([Table 1](#T1){ref-type="table"} and [Supplementary Table 5](#SD1){ref-type="supplementary-material"}, column 'Combined Stage 1&2') revealed two additional significantly associated loci: 2p13.3(*ETAA1*, rs1486134, OR=1.14, 95%CI:1.09--1.19, P=3.36×10^−9^) and 7p13(*SUGCT*, rs17688601, OR=0.88, 95%CI:0.84--0.92, P=1.41×10^−8^). Promising signals ([Supplementary Table 7](#SD1){ref-type="supplementary-material"}) arose at 18q21.2(*GRP*, rs1517037, OR=0.87, 95%CI:0.83--0.92, P=3.17×10^−7^), 12q24.31(*HNF1A,* rs7310409, OR= 1.11, 95%CI:1.06--1.15, P=6.34×10^−7^), 1p13.1(*WNT2B*, rs351365, OR=0.89, 95%CI:0.85--0.93, P=7.39×10^−7^), and 20q13.11 (rs6073450, OR=1.11, 95%CI:1.06--1.15, P=9.21×10^−7^).

We identified and replicated a novel region for association on 17q25.1 ([Fig. 4a](#F4){ref-type="fig"}). Two highly correlated variants (rs11655237 and rs7214041, r^2^=0.95) were associated with pancreatic cancer risk. Variant rs7214041 is to *LINC00673* (long inter-genic non-protein coding RNA 673). rs11655237, a non-coding transcript variant, shows significant DNase hypersensitivity in multiple cancer cell lines and binds transcription factors including *P300, FOXA1, FOXA2,* and the DNA repair protein *RAD21* according to HaploReg v2^[@R19]^. HaploRegV2 also indicated rs7214041 alters regulatory motifs for HNF1^[@R19]^. Interestingly, we also found suggestive evidence of an association with rs7310409 located at the *HNF1A* locus (12q24.31, [Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"} and [Supplementary Table 7](#SD1){ref-type="supplementary-material"}). A recent study of the pancreatic cancer transcriptome suggests HNF1A may act as a tumor suppressor in pancreatic cancers^[@R20]^. Variation in *HNF1A* has been associated with risk of Type 2 diabetes^[@R21],[@R22]^, a well-established risk factor for pancreatic cancer^[@R23]--[@R25]^, and maturity onset diabetes of the young (MODY)^[@R26]^. Furthermore, variants in *HNF1A* (in particular rs7310409) and *HNF4A* were identified as risk factors for pancreatic cancer in pathway-based and candidate-SNP-based analyses of the PanScan data^[@R27],[@R28]^.

We also identified significant association for two variants in high LD (rs9854771 and rs1515496, r^2^=0.99) located in an intron of *TP63* on 3q29 ([Fig. 4b](#F4){ref-type="fig"}). p63 is a p53 homologue implicated in tumorigenesis and metastasis^[@R29]^ by playing a role in cell-cycle arrest and apoptosis. Overexpression of p63 can mimic p53 activation in certain experimental models^[@R30]^. Interestingly, different isoforms of p63 have opposing effects; TAp63 has tumor suppressive effects while DNp63 has oncogenic effects^[@R31]^. Danilov and colleagues suggested DNp63α was the predominant isoform in pancreatic cancer cell lines and promoted pancreatic cancer growth, motility and invasion^[@R32]^. Previous GWAS studies of lung cancer and bladder cancer have demonstrated significant evidence of association for SNPs in *TP63*^[@R33]--[@R37]^. HaploReg query of this region showed that both are predicted to be conserved elements via GERP, suggesting functional roles.

Our analysis revealed genome-wide significance in a region on 2p13.3 (rs1486134). A pancreatic cancer GWAS in Han Chinese subjects^[@R12]^ found suggestive evidence for another SNP on 2p13.3 (rs2035565) ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). High LD is present throughout this region ([Fig. 4c](#F4){ref-type="fig"}), including strong LD between rs1486134 and rs2035565 in European and Asian populations based on 1000 Genomes^[@R15]^ samples (r^2^=0.91 and r^2^=0.90 respectively). This region includes the gene *ETAA1 (*Ewing tumor-associated antigen 1), alias *ETAA16,* that may function as a tumor-specific cell surface antigen in the Ewing's family of tumors^[@R38]^.

We observed significant association on 7p13 for rs17688601, located in an intron of the *SUGCT* (succinyl-CoA:glutarate-CoA transferase) gene (alias *c7orf10*) ([Fig. 4d](#F4){ref-type="fig"}). This variant is predicted in HaploREGV2 to alter binding of HNF1-4 and other DNA binding proteins^[@R19]^. The SUGCT protein is involved in glutarate metabolism and mutations in this gene are associated with glutaric aciduria^[@R39]^. While there is evidence of altered tricarboxylic acid cycle metabolism in pancreatic cancer^[@R40]^, the role of this gene in pancreatic cancer risk is unclear.

Combined Stage 1 and Stage 2 identified suggestive evidence of association (P\<1×10^−6^) in four regions: 12q24.31(*HNF1A*) ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}), 18q21.2(*GRP*) ([Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}), 1p13.1(5′ of *WNT2B*) ([Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}), and 20q13.11 ([Supplementary Fig. 3d](#SD1){ref-type="supplementary-material"}). GRP (gastrin releasing peptide) production has been associated with pancreatic tumor growth in vitro^[@R41]^. WNT signaling plays an important role in pancreas development. *WNT2B* (Wingless-Type MMTV Integration Site Family, Member 2B) is overexpressed in pancreatic cancer and has been associated with decreased survival^[@R42]^. The 20q13.11 variant is located \~20kb of the HNF4A (MODY) gene, mutations of which are associated with early-onset diabetes^[@R43]^.

In the PanC4 study we observed 11 SNPs on chromosome 9q31.3 ([Supplementary Fig. 3e](#SD1){ref-type="supplementary-material"}) in moderate to high LD (r^2^ values between 0.6 and 1) with p-values from 7.00×10^−8^ to 2.73×10^−6^, including rs10991043 (OR=1.19, 95%CI:1.12--1.26, P=7.00×10^−8^) nearby the *SMC2* (structural maintenance of chromosome 2) gene. This gene plays an important role in DNA repair in humans. While there was no evidence of association in the other study populations examined, the strong signal across multiple SNPs in PanC4 suggest that this region merits further investigation.

Further functional characterization of these associated regions is needed, including examining if these SNPs are functional through eQTL. Performing eQTL analysis of pancreatic tissues is challenging. Normal pancreatic tissue is primarily comprised of acinar cells (\>90%), but pancreatic ductal adenocarcinoma has a ductal phenotype, and the appropriate normal tissue to analyze is debatable because the cell of origin of pancreatic ductal adenocarcinomas is debated. eQTL analysis of pancreatic tumor tissue is also problematic because the tumor tissue of a pancreatic ductal adenocarcinomas contains a variable mixture of cell types including fibroblasts, multiple types of immune cells, non-neoplastic pancreatic cells and cancer cells, with cancer cells representing only a minority of the total cell population. Furthermore, gene expression analysis of normal pancreatic tissue is often limited by the RNA degradation associated with high level RNAase expression in pancreatic acinar cells. An ideal study of pancreatic eQTLs for pancreatic cells would take into account these challenges.

Smoking is a well-established risk factor for pancreatic cancer^[@R44]--[@R47]^. For all nine SNPs identified in [Table 1](#T1){ref-type="table"} and [Supplementary Table 7](#SD1){ref-type="supplementary-material"}, we conducted an analysis stratified by smoking status (ever smoker vs. never smoker) in PanC4 samples. No qualitative differences in effect size between current smokers and never smokers were observed (results not shown). Furthermore, when we included an interaction term in the model, this term was not significant at the 0.05 level.

We estimated the heritability of pancreatic cancer due to common GWAS SNPs using data from PanC4 samples of Caucasian ancestry using only directly genotyped SNPs(3,828 cases, 3,551 controls and 620,357 SNPs) as well as the combined dataset (7,032 cases 6,866 controls 268,681 SNPs). Using a disease prevalence of 0.0149, reflecting the lifetime risk of pancreatic cancer, we estimated that 16.4% (95%CI: 10.4%--22.4%) in PanC4 and 13.1% (95%CI 9.9%--16.3%) for the combined dataset of the total phenotypic variation was explained by genome-wide common SNPs. The established associated regions (loci in [Table 1](#T1){ref-type="table"} and [Supplemental Table 3](#SD1){ref-type="supplementary-material"}), accounted for 3.0% (95%CI: 2.0%-3.9%) and 2.1%(95%CI 1.7%-3.1%) of the total phenotypic variation in the Panc4 population and the combined dataset, respectively.

We identified several novel regions involved in pancreatic cancer susceptibility, and provided additional evidence to support many of the established associations. While it is of interest that many of these highly associated variants are located in the introns of genes, these associations could be due to more distant genomic effects. Follow-up studies, including functional studies, are needed to fully understand how these variants (either directly or indirectly) impact risk of pancreatic cancer. Our work highlights the importance of common variation in pancreatic cancer risk.

Online Methods {#S3}
==============

Stage 1 Methods {#S4}
---------------

### PanC4 Quality Control {#S5}

In total, 8052 individuals were selected for genotyping from studies participating in the Pancreatic Cancer Case-Control Consortium (PanC4). Participating sites included: The Central Europe study coordinated by the International Agency for Research on Cancer (IARC/Central Europe)^[@R48]^, Johns Hopkins Hospital^[@R49],[@R50]^, Mayo Clinic^[@R51]^, MD Anderson Cancer Center^[@R52]^, Memorial Sloane-Kettering Cancer Center^[@R53]^, University of Toronto^[@R54]^, Queensland^[@R55]^, University of California San Francisco (UCSF)^[@R56]^, and Yale University^[@R57]^ ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Cases were defined as individuals with adenocarcinoma of the pancreas. DNA samples from these individuals from PanC4, 180 study duplicates, 176 HapMap control samples, and 26 replicates from the previous pancreatic cancer GWAS PanScan 2^[@R10]^, were genotyped on the IlluminaHumanOmniExpressExome-8v1 array at the Johns Hopkins Center for Inherited Disease Research (CIDR). Genotypes were called using GenomeStudio version 2011.1, Genotyping Module 1.9.4 and GenTrain version 1.0.

Genotyping results were inspected for quality by assessing the missing call rate, allelic imbalance, heterozygosity, discordance in reported versus genotyped gender, relatedness, ancestry and chromosomal anomalies. Unexpected relatedness between pairs of samples was assessed using the method of moments^[@R58]^ implemented in *SNPRelate*^[@R59]^. The median genotype call rate was 99.9%, with all individuals having a call rate greater than 98%. After removing individuals with excessive allele sharing, duplicates and subjects with incomplete information on age, 7,956 subjects (4,164 cases and 3,792 controls) were available for statistical analyses ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). SNPs with the following characteristics were excluded from statistical analyses: positional duplicates, more than two discordant calls in study duplicates, technical failures or missing call rate greater than 2%, more than one Mendelian error in HapMap control trios, Hardy-Weinberg equilibrium p-value\<10^−6^, sex difference in allele frequency greater than 0.2 for autosomes/XY in samples of European ancestry, and minor allele frequencies (MAF) less than 0.005. Overall 654,470 SNPs passed the quality control filters applied; the median missing call rate was 0.024% and 98% of SNPs had a missing call rate less than 1% ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

### PanScan 1 and PanScan 2 Quality Control {#S6}

PanScan 1 and PanScan 2 data were obtained from dbGAP^[@R60],[@R61]^ (dbGaP study accession: phs000206.v4.p3). Data from all participating sites apart from Group Health (which required a separate data sharing agreement) were included in the analysis. Previously published PanScan 1^[@R9]^ and PanScan 2^[@R10]^ studies used the Illumina HumanHap550 and Illumina Human 610-Quad chips respectively. Quality control was performed as described above for PanC4. Forty-five unexpected duplicates between PanScan 1, PanScan 2, and PanC4 were identified and removed from analyses of the PanScan datasets. After data cleaning, 528,179 SNPs and 3,746 individuals (1,856 cases, 1,890 controls) remained in PanScan 1, and 557,555 SNPs and 3,300 individuals (1,618 cases and 1,682 controls) remained in PanScan 2 (See [Supplementary Table 4](#SD1){ref-type="supplementary-material"}).

### Association Analysis {#S7}

To investigate population structure, principal components analysis (PCA) was conducted separately for PanC4, PanScan 1 and PanScan 2 using *SNPRelate*^[@R59]^ ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). Genotype imputation was performed separately for PanScan 1, PanScan 2 and PanC4 using IMPUTE v2^[@R14]^. Since PanScan 1 and PanScan 2 SNPs were originally mapped using an older genome assembly (NCBI build 36), we converted their genome position to genome assembly NCBI build 37 by using LIFTOVER. Markers not identified in the build 37 assembly were removed. To decrease computational time, we pre-phased genotypes to produce best-guess haplotypes using SHAPEIT v2 software^[@R62]^. Both 1000 Genomes^[@R15]^ Phase I-integrated haplotypes (release Dec 2013) and HapMap3^[@R16]^ (release \#2,2009) were used as reference panels during imputation.

After imputation, SNPs with quality scores \< 0.3 were excluded from all subsequent analysis. Only SNPs directly genotyped in either PanC4, PanScan 1, or PanScan 2 and passing quality control filters were retained for analysis. This resulted in 866,891 SNPs in the Combined Stage 1 analysis. The expected genotype counts were then analyzed using the frequentist test option of SNPTEST^[@R63]^. Decade of age and eigenvectors from PCA were included as covariates. The number of eigenvectors to include was chosen based on inspection of the scree plot and p-values from association between eigenvectors and pancreatic cancer status. The results from each study were then combined using a fixed-effects inverse standard error approach implemented by METAL^[@R17]^ (see [Supplementary Table 5](#SD1){ref-type="supplementary-material"}, column 'Combined Stage 1'). Test statistic inflation (λ), was estimated to be 1.025 for PanC4, 0.998 for PanScan 1, and 1.017 for PanScan 2. Test statistics for PanC4 and PanScan 2 were adjusted to account for small amounts of population stratification using METAL's genomic control option. Our sample size gives us over 80% power to detect an odds ratio of 1.2 for SNPs with a minor allele frequency greater than 0.20. Manhattan and QQ plots of PanC4 GWAS are shown in [Fig. 2](#F2){ref-type="fig"} and [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}, respectively. Manhattan and QQ plots showing association results from the Combined Stage 1 analysis are shown in [Fig. 3](#F3){ref-type="fig"} **and** [Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}. To examine whether our association results were confounded by population stratification, we conducted a secondary analysis, restricting our samples to those of European ancestry based on a PCA analysis performed with PanC4 and Hapmap3 samples. The loci identified through association testing did not change, and their odds ratios and p-values did not vary significantly (results not shown).

Stage 2 Methods {#S8}
---------------

### PANDoRA Replication Study {#S9}

Twenty-five SNPs from 23 independent regions identified as showing evidence of association (P\<1×10^−5^) in either the PanC4 analysis or the Combined Stage 1 analysis, were genotyped in samples from the PANcreatic Disease ReseArch (PANDoRA)^[@R18]^ consortium with TaqMan technology. These samples were drawn from case-control studies in six European countries: Czech Republic, Germany, Greece, Italy, Lithuania, and Poland. In total, 2497 cases with pancreatic cancer and 4611 controls were genotyped. 8% of samples were duplicated and overall concordance was \>99%. [Supplementary Table 6](#SD1){ref-type="supplementary-material"} shows the features of the PANDoRA dataset. Samples missing more than 2 SNPs (\~15%) or missing covariate information were excluded from analyses. In total, 2,287 cases and 4,205 controls from the PANDoRA study remained after quality control.

Because PANDoRA is a collection of samples from various centers, we analyzed each country separately. Logistic regression models with additive effects of each allele were fit, as implemented in PLINK^[@R64]^ ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}, column 'PANDoRA'). Two SNPs, rs16867971 for Greece and rs10850078 for Lithuania, showed evidence of departure from HWE in controls (P\<0.001). The SNP violating HWE was not analyzed for that country. A final fixed-effects meta-analysis of PanC4, PanScan 1, PanScan 2, and PANDoRA (Combined Stage 1 and 2 analysis) was then conducted using METAL^[@R17]^ on the 25 SNPs chosen for inclusion in Stage 2. Results are in [Supplementary Table 5](#SD1){ref-type="supplementary-material"}, column 'Combined Stage 1&2'. To further interrogate these regions we examined all 1000G imputed SNPs (as described above) in regions with significant or suggestive (P\<1×10^−6^) evidence of association ([Fig. 4](#F4){ref-type="fig"} and [Supplemental Fig. 3](#SD1){ref-type="supplementary-material"}).

In our Combined Stage 1 analysis ([Supplementary Table 5](#SD1){ref-type="supplementary-material"}, column 'Combined Stage 1'), two SNPs selected for replication were observed to have heterogeneity p-values below 0.001. When restricting our analysis to individuals of European ancestry, heterogeneity p-values from the meta-analysis remained virtually unchanged, implying that the heterogeneity was not due to population stratification. One SNP, rs16867971, was directly genotyped in PanC4 and imputed in PanScan 1 and PanScan 2. We found evidence of association for rs16867971 in PanC4, but not in PanScan 1 or PanScan 2 (P\>0.05). The second SNP, rs6706539, was also directly genotyped in PanC4 and imputed in PanScan 1 and PanScan 2. For rs6706539, allele A was associated with increased risk in PanScan 1 and PanScan 2 (P=0.008 and P=0.04, respectively) but protective in PanC4 (P=3.4×10^−6^). Upon examination of the imputed and non-imputed SNPs adjacent to rs6706539, we found that r^2^ values between this SNP and other SNPs within 10kb were low, ranging from 0.05 to 0.18 in 1000 Genomes CEU samples. It is possible that this low LD made imputation of this SNP rather difficult. Additionally, inspection of the alleles coded as reference and alternate alleles for this SNP in PanC4 and 1000 Genomes suggests that this oddity is not due to differences in strand alignment.

Forest plots of our top hits ([Supplemental Fig. 5a--5i](#SD1){ref-type="supplementary-material"}) showing the magnitude of odds ratios for each study population show that in the majority of the "top" SNPs, those with p-value \<1×10^−6^, the direction of the effect was consistent across populations. Additionally, none of the top SNPs showed significant heterogeneity (at the 0.05 level) in the Combined Stage 1 and Stage 2 analysis. However, in many instances the effect size in the PanScan I population was smaller than the association observed in PanScan II, PanC4 and PANDoRA. We conducted a random effects meta-analysis as well and overall the results were consistent with the results observed from the fixed-effect meta-analysis (results not shown).

### Heritability Analysis {#S10}

Heritability analysis was performed using GCTA^[@R65]^ software. This analysis estimates the percentage of phenotypic variance explicated by common SNPs. We assumed a prevalence of 0.0149 (risk to age 90 in the US Caucasian population; SEER data collected in 2009--2011). We excluded individuals not clustering with HapMap^[@R16]^ CEU (CEPH- Utah residents with ancestry from northern and western Europe) samples in PCA analysis as well as individuals with estimated relationships \> 0.05 or missing genotype rate \>0.01. SNPs with missing rate\>0.05, MAF \<0.01 and HWE p-value\<5×10^−4^ were also excluded. We estimated the overall heritability in the PanC4 study using SNP data, as well as the heritability attributed to the 12 regions with significant evidence of association in the Caucasian population plus the 6 suggestive regions identified.

### HaploReg {#S11}

HaploReg is a tool used for exploring functional annotations of non-coding variants. For each variant and region identified in this study, we used HaploReg to gain insight into functional annotations including chromatin state (promoters and enhancers), conserved regions, variant effect on regulatory motifs and protein binding sites. Regions were defined by SNPs with r^2^\>0.8 to the associated SNP.
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======================
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![Manhattan plot of PanC4 association analysis. Loci previously associated with pancreatic cancer in Caucasians are shown in black, 2p13.3 in blue and novel loci in red.](nihms695333f2){#F2}
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###### 

Regional association and linkage disequilibrium (LD) plots for four novel genome-wide significant loci: (a) 17q25.1, (b) 3q29, (c) 2p13.3, and (d) 7p13. Association p-values are shown for three analyses: PanC4 only (black circles), Combined Stage 1 (PanC4, PanScan 1, and PanScan 2) (grey circles), and Combined Stage 1 and 2 (PanC4, PanScan 1, PanScan 2, and PANDoRA) (red circles). LD plots are based on 1000 Genomes European samples.
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###### 

Significant (P\<5×10^−8^) association results for pancreatic cancer

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                        Stage 1               Stage 2                                                                          
  ----------------------------------------- --------------------- ------------------------------------- --------------------- --------------------- --------------------- --------------------- -------------- --
  17q25.1[h](#TFN8){ref-type="table-fn"}\   T/C                   maf[e](#TFN5){ref-type="table-fn"}\   0.146; 0.110          0.139; 0.129          0.149; 0.116                                0.135; 0.114   
  rs11655237\                                                     cases;controls                                                                                                                               
  70,400,166\                                                                                                                                                                                                  
  *LINC00673*                                                                                                                                                                                                  

  info[f](#TFN6){ref-type="table-fn"}       0.963                 g                                     g                                                                                                      

  OR (CI)[g](#TFN7){ref-type="table-fn"}    1.38 (1.26 -- 1.52)   1.09 (0.96 -- 1.25)                   1.34 (1.16 -- 1.55)   1.27 (1.19 -- 1.36)   1.24 (1.10 -- 1.40)   1.26 (1.19 -- 1.34)                  

  p-value                                   1.38×10^−10^          1.95×10^−1^                           2.95×10^−4^           6.74×10^−12^          6.40×10^−4^           1.42×10^−14^                         

  17q25.1[h](#TFN8){ref-type="table-fn"}\   T/C                   maf\                                  0.148; 0.112          0.140; 0.133          0.150; 0.117                                0.139; 0.117   
  rs7214041\                                                      cases;controls                                                                                                                               
  70,401,476\                                                                                                                                                                                                  
  *LINC00673*                                                                                                                                                                                                  

  info                                      g                     0.966                                 0.96                                                                                                   

  OR (CI)                                   1.38 (1.26 -- 1.51)   1.07 (0.93 -- 1.22)                   1.33 (1.15 -- 1.53)   1.26 (1.18 -- 1.35)   1.25 (1.11 -- 1.41)   1.26 (1.19 -- 1.34)                  

  p-value                                   1.95×10^−10^          3.36×10^−1^                           3.69×10^−4^           2.67×10^−11^          3.37×10^−4^           2.88×10^−14^                         

  2p13.3\                                   G/T                   maf\                                  0.302; 0.275          0.305; 0.292          0.305; 0.276                                0.292; 0.273   
  rs1486134\                                                      cases;controls                                                                                                                               
  67,639,769\                                                                                                                                                                                                  
  *ETAA1* (2236bp 3′)                                                                                                                                                                                          

  info                                      g                     g                                     g                                                                                                      

  OR (CI)                                   1.14 (1.06 -- 1.22)   1.06 (0.96 -- 1.18)                   1.15 (1.03 -- 1.28)   1.13 (1.08 -- 1.19)   1.16 (1.06 -- 1.27)   1.14 (1.09 -- 1.19)                  

  p-value                                   5.96×10^−5^           1.57×10^−1^                           5.18×10^−3^           8.35×10^−7^           9.42×10^−4^           3.36×10^−9^                          

  7p13\                                     A/C                   maf\                                  0.241; 0.263          0.218; 0.254          0.237; 0.268                                0.254; 0.277   
  rs17688601\                                                     cases;controls                                                                                                                               
  40,866,663\                                                                                                                                                                                                  
  *SUGCT*                                                                                                                                                                                                      

  info                                      g                     g                                     g                                                                                                      

  OR (CI)                                   0.89 (0.83 -- 0.96)   0.82 (0.73 -- 0.91)                   0.85 (0.76 -- 0.94)   0.87 (0.82 -- 0.91)   0.91 (0.83 -- 1.00)   0.88 (0.84 -- 0.92)                  

  p-value                                   1.98×10^−3^           1.66×10^−4^                           8.72×10^−3^           9.77×10^−8^           3.93×10^−2^           1.41×10^−8^                          

  3q29\                                     A/G                   maf\                                  0.328; 0.362          0.336; 0.366          0.325; 0.356                                0.341; 0.356   
  rs9854771\                                                      cases;controls                                                                                                                               
  189,508,471\                                                                                                                                                                                                 
  *TP63*                                                                                                                                                                                                       

  info                                      g                     0.998                                 0.998                                                                                                  

  OR (CI)                                   0.86 (0.81 -- 0.92)   0.88 (0.80 -- 0.90)                   0.87 (0.79 -- 0.97)   0.87 (0.83 -- 0.92)   0.93 (0.86 -- 1.01)   0.89 (0.85 -- 0.93)                  

  p-value                                   3.10×10^−5^           7.94×10^−3^                           1.55×10^−2^           4.08×10^−8^           1.01×10^−1^           2.35×10^−8^                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cytogenetic regions according to NCBI Human Genome Build 37 and NCBI's Map Viewer

SNP position according to NCBI Human Genome Build 37

Results from the Combined Stage 1 meta-analysis of PanC4, PanScan 1, and PanScan 2

Results from the Combined Stage 1 and 2 meta-analysis of PanC4, PanScan 1, PanScan 2, and PANDoRA

MAF- minor allele frequency

Quality of imputation metric. See online methods for more detail. If snp is genotyped and not imputed, a 'g' is reported

Allelic Odds Ratio and corresponding 95% Confidence Interval

R^2^\>0.95

[^1]: These authors contributed equally to this work.
